IP Library Granted Patent US 9,776,971
Granted Patent B2
US 9,776,971 · App. 13/228,527 · Granted Oct 3, 2017

Opioid and opioid-like compounds and uses thereof

Inventors: Edwin S. C. Wu (Cary, NC); Mao-Hsiung Yen (Taipei, TW); Chin-Tsai Fan (Tainan County, TW)
Assignee: TaiwanJ Pharmaceuticals Co., Ltd.
C07D221/28A61K31/485A61K38/21A61K45/06C07D453/00C07D489/00C07D489/02C07D489/08Y10S514/893Y10S514/894
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,776,971
App. No.
13/228,527
Granted
Oct 3, 2017
Kind
B2
Abstract

The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage.

Claims (11)

1. A method for treating organ damage selected from liver damage and kidney damage, a disease associated with overproduction of TNF-α selected from the group consisting of Crohn's disease and pulmonary fibrosis, comprising administering to a subject in need thereof, a compound selected from the group consisting of naltrexone, nalmefene and mixtures thereof;

or

enantiomers, diastereoisomers, or pharmaceutically acceptable salts thereof.

2. A method of treating organ damage selected from liver damage and kidney damage, comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount, at a daily dose of from 2 mg to 100 mg, of a compound of claim 1 .

3. A method of treating a disease associated with overproduction of TNF-α selected from the group consisting of Crohn's disease, and pulmonary fibrosis, comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount, at a daily dose of from 2 mg to 100 mg, of a compound of claim 1 .

4. A method of treating a disease associated with overproduction of TNF-α consisting of pulmonary fibrosis, comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount, at a daily dose of from 2 mg to 100 mg, of naltrexone or nalmefene.

5. The method of treating liver or kidney damage, wherein a pharmaceutical composition comprising naltrexone or nalmefene is administered in combination with at least one other therapeutic agent selected from the group consisting of antibiotics, antimicrobials, antivirals, vaccines, interferons, and the like.

6. The method of claims 2 , 3 , or 4 , wherein the pharmaceutical composition is administered orally.

7. The method of claims 2 , 3 , or 4 , wherein the pharmaceutical composition is administered parenterally.

8. The method of claim 5 wherein the pharmaceutical composition is administered orally.

9. The method of claim 5 wherein the pharmaceutical composition is administered parenterally.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2014
From: JENKEN BIOSCIENCES, INC.
To: TAIWANJ PHARMACEUTICALS CO., LTD.
Reel/Frame 033749/0930 →
Continuity (6)
Continuation 12400344 · Mar 9, 2009
Division 11104281 · Apr 12, 2005
Continuation In Part 10936431 · Sep 8, 2004
Continuation In Part PCTUS0315461 · May 16, 2003
Provisional Application 60518448 · Nov 7, 2003
Related Publication 20120114599A1 · May 10, 2012